Advertisement
Screener

Vor Biopharma Inc. (VOR) Graph

VOR Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $25.92M; Operating expenses $47.85M; Net income -$62.81M.
  • 2026-03-31: Research and development $17.59M; Operating expenses $35.16M; Net income -$219.58M.
  • 2025-12-31: Research and development $19.19M*; Operating expenses $35.96M*; Net income $1.72B*.
  • 2025-09-30: Research and development $14.14M; Operating expenses $28.11M; Net income -$812.68M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$25.92M$47.85M-$62.81M
2026-03-31$17.59M$35.16M-$219.58M
2025-12-31$19.19M*$35.96M*$1.72B*
2025-09-30$14.14M$28.11M-$812.68M
2025-06-30$261.50M$274.28M-$1.57B
2025-03-31$26.70M$33.29M-$32.49M
2024-09-30$21.82M$28.51M-$27.56M
2024-06-30$21.82M$29.04M-$27.84M
2024-03-31$24.32M$32.33M-$30.80M
2023-09-30$27.61M$35.32M-$33.19M
2023-06-30$23.90M$32.17M-$29.98M
2023-03-31$21.91M$30.42M-$28.43M
2022-09-30$16.88M$24.10M-$23.79M
2022-06-30$15.33M$21.79M-$21.66M
2022-03-31$15.28M$22.80M-$22.74M
2021-09-30$12.93M$18.60M-$18.55M
2021-06-30$12.97M$18.38M-$18.37M
2021-03-31$8.94M$13.73M-$13.72M
2020-09-30$8.14M$11.79M-$11.79M
2020-06-30$5.97M$8.04M-$8.04M
2020-03-31$6.17M$7.88M-$7.85M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesNet income
2026-06-30$43.52M$83.01M-$282.39M
2025-06-30$288.20M$307.57M-$1.61B
2024-06-30$46.15M$61.36M-$58.64M
2023-06-30$45.81M$62.60M-$58.41M
2022-06-30$30.61M$44.59M-$44.40M
2021-06-30$21.91M$32.11M-$32.09M
2020-06-30$12.15M$15.92M-$15.89M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesNet income
2025-09-30$302.34M$335.68M-$2.42B
2024-09-30$67.96M$89.87M-$86.20M
2023-09-30$73.42M$97.91M-$91.60M
2022-09-30$47.49M$68.69M-$68.18M
2021-09-30$34.84M$50.71M-$50.65M
2020-09-30$20.29M$27.70M-$27.67M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesNet income
2025-12-31$321.53M$371.64M-$695.98M
2024-12-31$93.31M$121.19M-$116.91M
2023-12-31$94.31M$126.04M-$117.86M
2022-12-31$64.55M$93.42M-$92.09M
2021-12-31$47.53M$69.02M-$68.90M
2020-12-31$31.62M$43.37M-$43.34M

Similar stocks

Stock NameCountryMarket CapPE Ratio
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10